Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920820 | 0.90 | PTPN1 (0.46) | RXRARXRBRXRGPTPN1PDK1 | |
| SCHEMBL1534047 | 0.87 | PTPN1 (0.44) | PTPN1LMNAHPGDKDM4ETSHR | |
| SCHEMBL11922989 | 0.87 | FAAH (0.39) | — | |
| SCHEMBL1534206 | 0.84 | MEN1 (0.42) | RXRARXRBRXRGPTPN1PDK1 | |
| SCHEMBL113286 | 0.84 | PTPN1 (0.42) | PTPN1MRGPRX4LMNAHPGDKDM4E | |
| SCHEMBL11908949 | 0.81 | PDK1 (0.38) | RXRARXRBRXRGPTPN1PDK1 | |
| SCHEMBL17692775 | 0.79 | MRGPRX4 (0.40) | RXRARXRBRXRGPTPN1PDK1 | |
| SCHEMBL20860622 | 0.79 | PTPN1 (0.40) | RXRARXRBRXRGPTPN1PDK1 | |
| SCHEMBL17692768 | 0.79 | PTPN1 (0.40) | RXRARXRBRXRGPTPN1PDK1 | |
| Benzoic Acid SCHEMBL27880930 | 0.78 | RXRA (0.53) | RXRARXRBRXRGMRGPRX4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622496-B | Tetracycline compound | 四相制药公司 | 2019-03-05 | — | — | CN | disclosed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| CN-105622496-A | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS INC | 2016-06-01 | — | — | CN | disclosed |
| CN-102596898-B | tetracycline compound | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-01-27 | — | — | CN | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| CN-102596898-A | Tetracycline compound | TETRAPHASE PHARMACEUTICALS INC | 2012-07-18 | — | — | CN | disclosed |
| EP-2470500-A2 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011025982-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | RXRA 3508/4885RXRB 3597/4885RXRG 3779/4885 |
| US-20120208788-A1 | Tetracycline Compounds | TUBA1A, TUBA1C, TUBB1 | RXRA 3736/4885RXRB 3816/4885RXRG 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.